Article
Combating subclonal evolution of resistant cancer phenotypes.
Nature communications - 1 Nov 2017
Brady Samuel W, McQuerry Jasmine A, Qiao Yi, Piccolo Stephen R, Shrestha Gajendra, Jenkins David F, Layer Ryan M, Pedersen Brent S, Miller Ryan H, Esch Amanda, Selitsky Sara R, Parker Joel S, Anderson Layla A, Dalley Brian K, Factor Rachel E, Reddy Chakravarthy B, Boltax Jonathan P, Li Dean Y, Moos Philip J, Gray Joe W, Heiser Laura M, Buys Saundra S, Cohen Adam L, Johnson W Evan, Quinlan Aaron R, Marth Gabor, Werner Theresa L, Bild Andrea H
Abstract excerpt
Metastatic breast cancer remains challenging to treat, and most patients ultimately progress on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations (subclones) within heterogeneous tumors. Here, we track the genetic and phenotypic subclonal evolution of four breast cancers through years of treatment to better understand how breast cancers become drug-resistant. Recurrently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.